HIV, Lenacapavir

GILD Data on Once-Yearly Lenacapavir for HIV Prevention Positive
Gilead Sciences' data on two novel, once-yearly formulations of lenacapavir for PrEP support the further development of the drug.
Reformulation of HIV prevention drug lenacapavir makes it last for a year
A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV prevention drug lenacapavir allows it to persist in the body for up to a year. In their paper published in The Lancet journal,
Gilead data suggest once-yearly shot of PrEP drug blocks HIV infection
Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against infection with just a
Gilead Presents New HIV Treatment And Cure Research Data
Gilead's CROI 2025 data highlights Biktarvy's sustained HIV/HBV suppression, lenacapavir's efficacy, and vesatolimod's safety in early HIV treatment.
HIV drug could offer yearlong protection with a single shot
A new formulation of Gilead's HIV prevention drug, lenacapavir, has shown promise in providing yearlong protection with just one injection. The study, published in The Lancet, evaluated the pharmacokinetics, safety and tolerability of two intramuscular formations of lenacapavir in participants ages 18-55 without HIV.
Gilead presents data for once-yearly lenacapavir for HIV prevention
Sciences presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of
Gilead plots trial of groundbreaking, once-a-year HIV prevention drug lenacapavir
Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.
First Clinical Data for Gilead’s Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet
(Nasdaq: GILD) today presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of lenacapavir, the company’s injectable HIV-1 capsid inhibitor, for the investigational use of HIV prevention as pre-exposure prophylaxis (PrEP).
Healio33m
How researchers were able to enroll adolescents in landmark HIV trial
Researchers here described how they were able to safely and ethically enroll adolescents in a landmark trial of a drug that ...
Newspoint on MSN5h
Get one injection in a year and get rid of the tension of HIV! It can be a boon for such people
Scientists have got success with a new injection of HIV. Taking this injection once a year can reduce the risk of HIV ...
Fierce Pharma1d
A once-yearly PrEP? Gilead's lenacapavir shows promise as company plots phase 3
After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...
Gilead Sciences (NasdaqGS:GILD) Advances HIV Treatment With Promising Lenacapavir And Biktarvy Data
Gilead Sciences (NasdaqGS:GILD) recently experienced a significant price movement, rising 24% in the last quarter. This ...
BioSpace9h
Gilead, GSK-ViiV Move Ahead With Long-Acting HIV Options Following Early-Stage Readouts
Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...
News-Medical.Net on MSN10h
Gilead’s capsid revolution meets our capsid solutions: Sino Biological – Engineering the tools to outsmart HIV
Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...
El Mundo on MSN13h
New advance against HIV: a single annual injection against the infection
Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...
Annual jab for HIV protection passes trial hurdle
Lenacapavir, which stops HIV from replicating inside cells, has passed early safety tests.